Drugs Acting on Autonomic Ganglia
-
Upload
dita-hasni -
Category
Documents
-
view
196 -
download
3
Transcript of Drugs Acting on Autonomic Ganglia
Drugs active at parasympathetic ganglia are equally effective at sympathetic ganglia, and vice versa. Nicotine stimulates postganglionic neuron receptors in the autonomic ganglia. Hexamethonium and mecamylamine effectively block these "nicotinic" receptorsites.
Drugs Acting on Autonomic Ganglia
Effects of Autonomic Ganglionic Blockade
Site Predominant tone Effects of ganglion blockade
Arterioles Sympathetic Arteriodilation, ↓PR, hypotension
Veins Sympathetic Venodilation, ↓venous return, ↓cardiac output, hypotension
Heart Parasympathetic Tachycardia
Iris Parasympathetic Mydriasis
CiliaryMuscle Parasympathetic Cycloplegia
GIT Parasympathetic ↓Tone and motility, constipation
Bladder Parasympathetic Urine retention
Salivary gland Parasympathetic Xerostomia(dry mouth)
Sweat gland Sympathetic Anhidrosis(absence of sweating)
Ganglion Blocks (Cont.)
A. Nicotine (high dose)
Nicotine is a poison with many undesirable actions. It is without therapeutic benefit and is deleterious to health. •Depending on the dose, nicotine stimulates (low doses) then inhibits (high doses) autonomic ganglia. •The stimulatory effects: increased BP and HR (due to release of transmitter from adrenergic terminals and from the adrenal medulla) and increased peristalsis and secretions. •At higher doses: fall in BP, decreased activity of the GI tract and bladder.
B. Trimetaphan&Mecamylamine
•Trimetaphan: IV only and short acting•Mecamylamine: can be given orally & has a long duration•They are be used in emergency hypertension
A. Competitive Neuromuscular blockers•
The first drug that was found to be capable of blocking the skeletal neuromuscular junction was curare.•Curare was used by native hunters of the Amazon in South America to paralyze animals. •The drug was ultimately purified and introduced into clinical practice in the early 1940s. •Although tubocurarineis considered to be the prototype agent in this class, it has been largely replaced by other agents.
Competitive Neuromuscular blockers (Cont.)
•Mechanism of action: They interact with the nicotinic receptors to competitively prevent the binding of acetylcholine. •They are pure antagonists i.e. they produce no initial stimulation.•They are antagonized by neostigmine.•These agents possess two or more quaternaryamines in their bulky ring structure, making them orally ineffective. Therefore, all neuromuscular blocking agents are administered IV.
TubocurarineAtracuriumCisatracuriumDoxacuriumMetocurineMivacuriumPancuroniumRocuroniumVecuronium
Competitive Neuromuscular blockers (Cont.)
Side Effects:•Tubocurarinemay release histamineand lower BP. •Atracuriummay release histamineand may provoke seizures.
Drug interactions:a. Cholinesterase inhibitors: Drugs such as neostigmine, physostigmine, pyridostigmine, and edrophonium: Antagonismb.Halogenatedhydrocarbon anesthetics(e.g. halothane): Potentiationc. Aminoglycoside antibiotics: Synergism(Drugs such as gentamicin or tobramycin inhibit acetylcholine release from cholinergic nerves by competing with calcium ions)d.Calcium-channel blockers:These agents may enhancethe neuromuscular block of tubocurarineand other competitive blockers as well as depolarizing blockers.
B. Depolarizing Neuromuscular Blockers(Succinylcholine, Decamethonium)
Mechanism of action•Succinylcholine(as an example) binds to the nicotinic receptor and acts like AChto depolarize the junction. However, succinylcholinepersists at high concentrations in the synaptic cleft for a relatively longer time and providing a prolonged stimulation. •The drug first causes the opening of the sodium channel associated with the nicotinic receptors, which results in depolarization of the receptor (Phase I). This leads to a transient twitching of the muscle (fasciculations). •With time, continuous depolarization gives way to gradual repolarizationas the sodium channel closes or is blocked. This causes a resistance to depolarization (Phase II) and a flaccid paralysis.
Succinylcholine(Cont.)
•They are potentiated by neostigmine. •Normally, the duration of action of succinylcholineis short, because it is rapidly oken down by plasma cholinesterase (pseudo-cholinennsterase). Genetic variants in which plasma cholinesterase levels are low or absent may suffer prolonged neuromuscular paralysis.•Therapeutic uses:Because of its rapid onset and short duration of action, succinylcholineis useful for endotrachealintubationand during electroconvulsive shocktreatment.
Succinylcholine(Cont.)
Adverse effects•Apnea: Administration of succinylcholineto a patient who is genetically deficient in plasma cholinesterase or has an atypical form of the enzyme can lead to prolonged apnea due to paralysis of the diaphragm.•Malignant hyperthermia: When halothane is used as an anesthetic, administration of succinylcholinehas occasionally caused malignant hyperthermia (with muscular rigidity and hyperpyrexia) in genetically susceptible people. This is treated by rapidly cooling the patient and by administration of dantrolene, which blocks release of Ca2+from the sarcoplasmicreticulum of muscle cells, thus reducing heat production and relaxing muscle tone.•Hyperkalemia: Succinylcholineincreases potassium release from intracellular stores. This may be particularly dangerous and cause cardiac arrest.